| Home Market Dynamics Macro Trends Sector Trends Company Insights AI Investing Strategies Sign Up Login |
| Currently, stocks in the health care sector show a strong performance driven by advancements in biotechnology, robust earnings from major companies, and a favorable market sentiment surrounding health-related investments. Recent discussions highlight significant activities in mergers and acquisitions, particularly among pharmaceutical giants, further reinforcing confidence in the sector. However, ongoing legal challenges faced by prominent companies, alongside trial failures reported by key players, create volatility and risk perceptions. Overall, the market remains optimistic due to innovation and strong corporate earnings despite these challenges. The price action of Health Care (XLV) sector is shaped by numerous forces, ranging from broad macroeconomic trends to company-specific performance and market structure. The trend sentiment at 0.2 is modestly bullish. The market sentiment at 0.6 is bullish. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next.XLV is likely to move up since both trend sentiment and market sentiment are positive. The positive sentiment force for Health Care sector is at 0.8, and the negative at -0.3 on 2026-08-03. The forces of Sentiment towards Fundamentals (2.2), Valuation Sentiment (1.8), Broad Market Trend (0.5), Option Sentiment (0.3), Sector Price Trend (0.2), and Price Level Sentiment (0) will drive up the price. The forces of and Market Risk Appetite (-1.7) will drive down the price. The sentiment for Broad Market Trend is calculated based on SPY trend. The sentiment for Sector Price Trend is calculated based on XLV trend. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Prefrence is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band. |
Sign up to reveice Sector Rotation Notification
| XLV | ||||||||||||||||
| Date | Attention | Price | StdDev | Price Level | RSI | Hourly RSI | Change | 10 Day Trend | Trend Sentiment | Hourly Trend Sentiment | Hourly StdDev | Market Sentiment | Action | P | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-03 | 1%(1.4%) | 162.26 | 1.41% | 54 | 60 | 60 | -0.18% | 0.18% | 0.2 | 0.1 | 0.4% | 0.6 | Long | 55% | 2.2 | 4.2 |
| 2026-08-02 | 3%(1.3%) | 0 | 0.8 | 2.2 | 6 | |||||||||||
| 2026-08-01 | 1%(1%) | 0 | 0.8 | 2.2 | 3.5 | |||||||||||
| 2026-07-31 | 2%(1%) | 162.56 | 1.41% | 57 | 53 | 55 | -0.56% | 0.12% | 0 | -0.2 | 1% | 0.9 | Short | 55% | 2.3 | -2.5 |
| 2026-07-30 | 1%(1%) | 163.48 | 1.42% | 66 | 56 | 26 | -1.67% | 0.06% | 0.3 | -0.2 | 1.2% | 1 | Short | 55% | 2.4 | 3.6 |
| 2026-07-29 | 1%(1%) | 166.25 | 1.41% | 97 | 59 | 29 | -0.62% | 0.5% | 1.3 | -0.2 | 0.8% | 1.3 | Wait | 50% | 2.8 | 1.8 |
| 2026-07-28 | 1%(1%) | 167.29 | 1.32% | 117 | 62 | 70 | 2.37% | 0.56% | 1.3 | 0.3 | 1.2% | 1 | Wait | 50% | 2.6 | 6.8 |
| 2026-07-27 | 0%(1.3%) | 163.42 | 1.07% | 83 | 47 | 55 | 0.53% | 0.12% | 0.5 | 0 | 0.6% | 0.8 | Long | 55% | 2.5 | -0.5 |
| 2026-07-26 | 1%(1.4%) | 0.4 | 0.9 | 2.1 | 3 | |||||||||||
| 2026-07-25 | 1%(1.3%) | 0.4 | 0.8 | 2 | 4 | |||||||||||
| Long is the preferred trading strategy with 55% chance of being right. Improving trend sentiment and positive hourly trend. Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. | ||||||||||||||||
| Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force. | ||||||||||||||||
| Analysis | ||
| ● Health Care Sector Check-Up: What Analysts Are Saying Right Now Mon. Sep 29, 2025 | ||
| Market News | ||
| 1 (7) 3 Healthcare Stocks With Fresh Dividend Hikes and Different Income Profiles McKesson, Encompass Health and Omega Healthcare Investors raised dividends, with payout ratios and yields showing varying levels of sustainability across the healthcare sector. (https://www.marketbeat.com/) Mon. Aug 3, 2026 | ||
| 2 (-3) Bristol Myers Squibb Stock Falls on Report of $400 Billion Merger Talks With AstraZeneca A merger between Bristol Myers Squibb and AstraZeneca would be one of the biggest pharma deals ever. AstraZeneca’s market capitalization stood at $264 billion as of Friday’s close, while Bristol Myers Squibb had a total valuation of $133 billion. (https://www.barrons.com/) Mon. Aug 3, 2026 | ||
| 3 (8) Baxter International Inc. stock outperforms competitors on strong trading day Shares of Baxter International Inc. BAX advanced 7.42% to $28.10 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 1.48% to 7,600.50 and the Dow Jones Industrial Average DJIA rising 1.32% to 53,178.41. Baxter International Inc. closed 6.33% short of its 52-week high of $30.00, which the company achieved on July 30th. (https://www.marketwatch.com/) Mon. Aug 3, 2026 | ||
| 4 (0) AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus AstraZeneca and Bristol Myers reportedly discuss a $400 billion merger as analyst assesses valuation, patent risks and regulatory hurdles. (https://www.benzinga.com/) Mon. Aug 3, 2026 | ||
| 5 (8) Analyst Calls Curium's $8 Billion Lantheus Buyout An 'Excellent Outcome' For Shareholders CapVest-backed Curium agrees to acquire Lantheus for up to $8B, expanding its global footprint in nuclear medicine. (https://www.benzinga.com/) Mon. Aug 3, 2026 | ||
| 6 (-6) AstraZeneca Investors See Little Logic in Bristol Tie-Up AstraZeneca Plc investors had a clear message for the UK drugmaker on Monday: they don’t like the idea of a $400 billion merger with Bristol-Myers Squibb Co. (https://www.bloomberg.com/) Mon. Aug 3, 2026 | ||
| 7 (8) Supernus to Combine with Indivior To Form CNS Biopharmaceutical Leader with Potential $2 Billion in Revenue Supernus and Indivior agree to merge in an all-stock deal, targeting $2.2 billion in revenue and $125 million in synergies. (https://www.benzinga.com/) Mon. Aug 3, 2026 | ||
| 8 (8) Integer Shares Rally On $127 Per Share KKR Offer Integer Holdings shares gained after KKR agreed to acquire the medical device company in a transaction valued at approximately $5.7 billion. (https://www.benzinga.com/) Mon. Aug 3, 2026 | ||
| 9 (8) Bristol Myers Squibb Stock Jumps on Report of $400 Billion Merger Talks With Big Rival The merger would be one of the biggest pharma deals ever. AstraZeneca’s market capitalization stood at $264 billion as of Friday’s close, while Bristol Myers Squibb had a total valuation of $133 billion. (https://www.barrons.com/) Mon. Aug 3, 2026 | ||
| 10 (6) KKR to Buy Device Maker Integer in $5.7 Billion Deal KKR has agreed to buy US medical device company Integer Holdings Corp. in an all-cash deal valued at about $5.7 billion. (https://www.bloomberg.com/) Mon. Aug 3, 2026 | ||
| 11 (8) Why Is Bristol-Myers Squibb Stock Surging Monday? Bristol Myers Squibb and AstraZeneca in talks for a $400B mega-merger, potentially creating the world's 4th-largest drugmaker. (https://www.benzinga.com/) Mon. Aug 3, 2026 | ||
| 12 (8) AstraZeneca holds talks with Bristol Myers Squibb over $400bn tie-up Deal would create world’s fourth-largest drugmaker by market value (https://www.ft.com/) Sun. Aug 2, 2026 | ||
| 13 (7) AstraZeneca Is Said to Have Explored Bristol Myers Merger AstraZeneca Plc has explored an acquisition of Bristol Myers Squibb Co., a megadeal that would create one of the world’s largest drugmakers, according to people familiar with the matter. (https://www.bloomberg.com/) Sun. Aug 2, 2026 | ||
| 14 (5) AstraZeneca and Bristol-Myers Squibb in talks over potential merger - Report AstraZeneca and Bristol-Myers Squibb in talks over potential merger - Report (https://www.investing.com/) Sun. Aug 2, 2026 | ||
| 15 (7) AbbVie Quietly Solved Its Biggest Problem—Now What? AbbVie posted strong Q2 revenue and EPS growth, and despite a post-earnings dip tied to the Apogee Therapeutics deal, analysts and dividend strength support shares reaching $300. (https://www.marketbeat.com/) Sun. Aug 2, 2026 | ||
| 16 (5) AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports U.K. pharmaceutical giant AstraZeneca is considering a deal to merge with its U.S. rival Bristol Myers Squibb. (https://www.cnbc.com/) Sun. Aug 2, 2026 | ||
| 17 (7) AstraZeneca, Bristol Myers Squibb Reportedly in Talks for $400 Billion Merger AstraZeneca in talks to merge with Bristol Myers Squibb, creating $400B pharma giant, while talks ongoing for months, antitrust scrutiny is expected. (https://www.benzinga.com/) Sun. Aug 2, 2026 | ||
About
Contact Us
Copyright ©2025 TheMarketUnfolds. All rights reserved. Denver, Colorado, USA